HF 4
The percentage of patients with a current diagnosis of heart failure due to LVD who are currently treated with an ACE inhibitor or Angiotensin Receptor Blocker, who are additionally treated with a beta-blocker licensed for heart failure, or recorded as intolerant to or having a contraindication to beta-blockers.
| Indicator | Year | Numerator | Denominator | Ratio | Centile |
|---|---|---|---|---|---|
| HF 4 | 2011 | 390 | 493 | 79.1% | |
| HF 4 | 2012 | 394 | 480 | 82.1% | |
| HF 4 | 2013 | 385 | 459 | 83.9% | |
| HF004 | 2014 | 140 | 154 | 90.9% | |
| HF004 | 2015 | 179 | 196 | 91.3% | |
| HF004 | 2016 | 275 | 310 | 88.7% | |
| HF004 | 2017 | 315 | 352 | 89.5% | |
| HF004 | 2018 | 355 | 390 | 91.0% | |
| HF004 | 2019 | 414 | 453 | 91.4% | |
| HF004 | 2020 | 420 | 458 | 91.7% | |
| HF006 | 2021 | 516 | 586 | 88.1% | |
| HF006 | 2022 | 572 | 608 | 94.1% | |
| HF006 | 2023 | 685 | 716 | 95.7% |
